14-3-3σ expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 949-955

  Chan, Sylvia Yat Yee ^a,b   To, Ka Fai ^a,b   Leung, Sing Fai ^a   Yip, William Wai Lun ^c   Mak, Michael Ko Fung ^d   Chung, Grace Tin Yun ^a,b   Lo, Kwok Wai ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Hong Kong Baptist Hospital   (Hong Kong)

^d ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

14 3 3 ; DNA methylation; Nasopharyngeal carcinoma; Prognostic marker; Radiotherapy

Indexed keywords

STRATIFIN; TUMOR MARKER; EXONUCLEASE; PROTEIN 14 3 3; SFN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA METHYLATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CANCER STAGING; CARCINOMA; DRUG SCREENING; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CARCINOMA; DNA METHYLATION; EXONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 77957334060     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000941     Document Type: Article

References (29)

1. Aitken A, Collinge DB, van Heusden BP, Isobe T, Roseboom PH, Rosenfeld G and Soll J: 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci 17: 498-501, 1992.
2. Bridges D and Moorhead GBG: 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE 2005: re10, 2005.
3. Tzivion G, Gupta VS, Kaplun L and Balan V: 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16: 203-213, 2006.
4. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica- Worms H: Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 227: 1501-1505, 1997.
5. Lodygin D and Hermeking H: Epigenetic silencing of 14-3-3 sigma in cancer. Semin Cancer Biol 16: 214-224, 2006.
6. Horie-Inoue K, and Inoue S: Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Semin Cancer Biol 16: 235-239, 2006.
7. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
8. Chan TA, Hermeking H. Lengauer C, Kinzler KW and Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
9. Laronga C, Yang HY, Neal C and Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106-23112, 2000.
10. Subramanian RR, Masters SC, Zhang H and Fu H: Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis. Exp Cell Res 271: 142-151, 2001.
11. Samuel T, Weber HO, Rauch P, Verdoodt B, Eppel JT, McShea A, Hermeking H and Funk JO: The G2/M regulator 14-3-3 sigma prevents apoptosis through sequestration of Bax. J Biol Chem 276: 45201-45206, 2001.
12. Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423-428, 2004.
13. Yang H, Zhao R and Lee MH: 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol Cancer Ther 5: 253-260, 2006.
14. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of nasopharynx. Int J Cancer 26: 127-132, 1980.
15. Cheung ST, Huang DP, Hui ABY, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM and Lee JC: Nasopharyngeal carcinoma cell line (C666-1) consistently harboring Epstein-Barr virus. Int J Cancer 83: 121-126, 1999.
16. Huang DP, HO JH, Chan WK, Lau WH and Lui M: Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 43: 936-939, 1989.
17. Busson P, Ganem G, Flores P, Mugneret F, Clausse B, Caillou B, Braham K, Wakasugi H, Lipinski M and Tursz T: Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 42: 599-606, 1988.
18. Li HM, Man C, Jin Y, Deng W, Yip YL, Feng HC, Cheung YC, Lo KW, Meltzer PS, Wu ZG, Kwong YL, Yuen AP and Tsao SW: Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer 119: 1567-1576, 2006.
19. Fleming ID, Cooper JS, Henson DE, et al (eds): AJCC Cancer Staging Manual (5th edition). Lippincott-Raven, Philadelphia, PA, pp31-39, 1997.
20. Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP and Lo KW: Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer 46: 171-180, 2007.
21. Hui AB, Or YY, Takano H, Tsang RK, To KF, Guan XY, Sham JS, Hung KW, Lam CN, van Hasselt CA, Kuo WL, Gray JW, Huang DP and Lo KW: Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125-8133, 2005.
22. Ferguson At, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
23. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5'CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
24. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi T: Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers. Oncogene 21: 2418-2424, 2002.
25. Henrique R, Jerónimo C, Hoque MO, Carvalho AL, Oliverira J, Teixeira MR, Lopes C and Sidransky D: Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol 24: 264-269, 2005.
26. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353, 2001.
27. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM and Eble JN: Loss of 14-3-3 sigma in prostate cancer and its precursors. Clin Cancer Res 10: 3064-3068, 2004.
28. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y and Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumor growth. Nature 417: 871-875, 2002.
29. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Marqreiter R and Amberger A: 14-3-3 sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279, 2005.